Actemra

(Tocilizumab)

ApprovedMonoclonal antibody

Tocilizumab is used to treat rheumatoid arthritis and other inflammatory conditions by reducing inflammation in the body. It is also used to treat severe COVID-19 in hospitalized patients.[2] Actemra is currently approved and in use across 61 indications[4].[1]

Actemra is one of 1028 small molecule programs targeting Leukemia. It is currently in Approved.

Indications

453

Total Trials

Active Trials

1,027

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

LeukemiaRecruiting

COVID-19Completed

UveitisNot yet recruiting

LymphomaCompleted

NecrosisActive, not recruiting

KidneyActive, not recruiting

Aneurysmal Subarachnoid HemorrhageRecruiting

Systemic SclerodermaUnknown

Nasopharyngeal CarcinomaActive, not recruiting

ObesityActive, not recruiting

LeukemiaPhase 1

Recruiting

COVID-19Approved

Completed

UveitisPhase 2

Not yet recruiting

LymphomaPhase 3

Completed

NecrosisPreclinical

Active, not recruiting

KidneyPreclinical

Active, not recruiting

Aneurysmal Subarachnoid HemorrhagePhase 1

Recruiting

Systemic SclerodermaPreclinical

Unknown

Nasopharyngeal CarcinomaPreclinical

Active, not recruiting

ObesityPreclinical

Active, not recruiting

Showing 10 of 61 indications

Competition

Competitive Landscape

414 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Actemra

Roche

Approved

2 2

Benadryl

PParkedale

Phase 3

2 3

Furmonertinib

AAllist Pharmaceuticals, Inc.

Phase 3

5 4

BPI-7711

BBeta Pharma Shanghai

Phase 3

3 5

Remeron

OOrganon and Co

Preclinical

1 6

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—7

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—8

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Treatment

1 10

PD-1 Inhibitors

BBioNTech US Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Recruiting

Metastatic Cancer

NCT06016179

Q2 2027

N/ARecruiting

Tocilizumab

NCT07006532

Phase 1Active, not recruiting

Tocilizumab

NCT03970226

Phase 2Active, not recruiting

Transplantation

NCT04395222

Phase 2Recruiting

Tocilizumab

NCT05845723

Phase 2Recruiting

Tocilizumab

NCT06430736

Clinical

Trials by Indication[1]

Rheumatoid Arthritis46 trials

Uncontrolled Study to Evaluate Efficacy of Tocilizumab in Patients With Moderate or Severe Rheumatoid Arthritis

Unknown status·SSpanish Foundation of Rheumatology·Phase 4·NCT02087696·122 enrolled

A Study of the Effects of RoActemra/Actemra on Vaccination in Patients With Rheumatoid Arthritis on Background Methotrexate (VISARA)

Completed· Roche logo

Roche·Phase 4·NCT01163747·91 enrolled

A Study of Tocilizumab in Combination With an Oral Contraceptive in Patients With Rheumatoid Arthritis

Completed· Roche logo

Roche·Phase 3·NCT01044498·46 enrolled

Show 43 more trials

Extension Study of Tocilizumab Long Term Treatment of Moderate to Severe Rheumatoid Arthritis Patients

Completed·CChugai Pharma Taiwan·Phase 3·NCT01347983·72 enrolled

A Long-Term Extension Study of WA22762 and NA25220 of Subcutaneous (SC) Tocilizumab (TCZ) in Moderate to Severe Rheumatoid Arthritis (RA)

Completed· Roche logo

Roche·Phase 3·NCT01662063·218 enrolled

Study of Tocilizumab in Combination With Methotrexate for Treatment of Moderate to Severe Rheumatoid Arthritis Patients

Completed·CChugai Pharma Taiwan·Phase 3·NCT01258712·86 enrolled

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice

Completed· Roche logo

Roche··NCT01474291·608 enrolled

An Observational Study to Evaluate the Clinical Effectiveness, Quality of Life, Safety and Tolerability of Tocilizumab (TCZ) in Patients With Rheumatoid Arthritis (RA) in Daily Clinical Practice

Completed· Roche logo

Roche··NCT02552940·140 enrolled

A Study of Tocilizumab (RoActemra/Actemra) in Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Participants With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biologic DMARD Therapy or the First Anti-TNF Biologic Agent

Completed· Roche logo

Roche·Phase 3·NCT02046603·162 enrolled

A Study to Understand How Effective is Tofacitinib When Compared to Other Advanced Treatments in Patients With Rheumatoid Arthritis

Completed· Pfizer logo

Pfizer··NCT06418529·21,340 enrolled

Non-Interventional Study of Tocilizumab Subcutaneous (SC) Monotherapy in Participants With Rheumatoid Arthritis (RA)

Completed· Roche logo

Roche··NCT02402686·353 enrolled

A Retrospective Cohort Study on the Risk of Serious Infections in Rheumatoid Arthritis Patients Receiving Tocilizumab

Unknown status·SSungkyunkwan University··NCT04115423·9,508 enrolled

A Study of Tocilizumab in Participants With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Non-Biological Disease-modifying Anti-rheumatic Drugs (DMARDs)

Completed· Roche logo

Roche··NCT01617005·50 enrolled

A Prospective Observational Study of Tocilizumab (RoActemra/Actemra) in Participants With Rheumatoid Arthritis

Completed· Roche logo

Roche··NCT01462162·122 enrolled

A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Participants With Moderate to Severe Active Rheumatoid Arthritis

Completed· Roche logo

Roche·Phase 3·NCT01194414·1,262 enrolled

A Phase IV Study to Evaluate the Effect of Subcutaneous (SC) Tocilizumab Administered to Participants With Rheumatoid Arthritis (RA) Assessed Using Disease Activity Score (DAS28)

Completed· Roche logo

Roche··NCT02534311·60 enrolled

Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis

Completed· Roche logo

Roche··NCT01579006·184 enrolled

A Time to Cardiovascular Event Analysis Comparing Tocilizumab to Other Biologics in Patients With Rheumatoid Arthritis (RA)

Completed· Roche logo

Roche··NCT02797769·48,950 enrolled

A Study on Safety and Efficacy of Tocilizumab (RoActemra/Actemra) Alone or in Combination With Non-Biologic Antirheumatics in Participants With Rheumatoid Arthritis

Completed· Roche logo

Roche·Phase 3·NCT01987479·150 enrolled

A Phase IIb Study for ALX-0061 Monotherapy in Subjects With Rheumatoid Arthritis

Completed·AAblynx, a Sanofi company·Phase 2·NCT02287922·251 enrolled

Evolution of Adipokines and Body Composition in Rheumatoid Arthritis Patients Receiving Tocilizumab Therapy

Completed·—·Phase 4·NCT02843789·109 enrolled

Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)

Completed· Regeneron logo

Regeneron·Phase 1·NCT02097524·105 enrolled

Efficacy and Safety Study of RoActemra (Tocilizumab) in Participants With Rheumatoid Arthritis

Completed· Roche logo

Roche··NCT02721004·592 enrolled

A Study to Evaluate Efficacy of Tocilizumab Administered as Monotherapy or in Combination With Methotrexate and/or Other Disease Modifying Antirheumatic Drugs (DMARDs) in Rheumatoid Arthritis (RA) Participants

Completed· Roche logo

Roche·Phase 3·NCT01941940·227 enrolled

A Study of Subcutaneous (SC) Tocilizumab (RoActemra/Actemra) in Participants With Active Rheumatoid Arthritis (RA) and Inadequate Response to Disease-Modifying Anti-Rheumatic Drugs (DMARDs)

Completed· Roche logo

Roche·Phase 3·NCT02046616·133 enrolled

Local, Non-Interventional Study of RoActemra (Tocilizumab) in Poland (ACT-POL): First-Line Treatment in Routine Clinical Practice of Participants With Rheumatoid Arthritis (RA)

Completed· Roche logo

Roche··NCT02234960·102 enrolled

Characterization of Non-Steroidal Anti-Inflammatory Drug (NSAID) Intake in Rheumatoid Arthritis (RA) Participants on Tocilizumab (RoACTEMRA®) Treatment

Completed· Roche logo

Roche··NCT03112213·135 enrolled

EMBRACE-SC: Observational Study of Subcutaneous (SC) Tocilizumab Alone or in Combination With Conventional Disease-Modifying Antirheumatic Drugs (cDMARDs) in Rheumatoid Arthritis

Completed· Roche logo

Roche··NCT02648035·200 enrolled

A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Severe Active Rheumatoid Arthritis, Comparing Tapering Versus Maintaining the Methotrexate Dosage

Terminated· Roche logo

Roche·Phase 4·NCT01661140·427 enrolled

Single-dose Study to Describe the Safety of Sarilumab and Tocilizumab in Patients With Rheumatoid Arthritis

Completed· Sanofi logo

Sanofi·Phase 1·NCT02404558·30 enrolled

A Study of Subcutaneous Tocilizumab as Monotherapy and/or in Combination With Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Rheumatoid Arthritis

Completed· Roche logo

Roche·Phase 3·NCT01941095·100 enrolled

A Study to Assess Efficacy With Respect to Clinical Improvement in Disease Activity and Safety of Tocilizumab in Patients Wtih Active Rheumatoid Arthritis.

Completed· Roche logo

Roche·Phase 3·NCT00754559·286 enrolled

An Extension Study of WA19926 of the Long-Term Safety of Tocilizumab (RoActemra/Actemra) in Patients With Early Moderate to Severe Rheumatoid Arthritis

Completed· Roche logo

Roche·Phase 3·NCT01664598·49 enrolled

Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Participants With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Non-Biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) and/or Anti-tumor Necrosis Factor (Anti-TNF) Therapy

Completed· Roche logo

Roche··NCT01362062·110 enrolled

A Long-term Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients With Rheumatoid Arthritis

Completed· Roche logo

Roche·Phase 3·NCT00721123·538 enrolled

Effect of Subcutaneous ACTEMRA on Inflamed Atherosclerotic Plaques in Patients With Rheumatoid Arthritis

Terminated·MMassachusetts General Hospital·Phase 4·NCT02659150·16 enrolled

An Observational Study of Tocilizumab (Actemra) in Participants With Moderate to Severe Rheumatoid Arthritis

Completed· Roche logo

Roche··NCT01741688·16 enrolled

A Non-Interventional Study of Rheumatoid Arthritis Patients Treated With RoActemra/Actemra (Tocilizumab) in Monotherapy

Completed· Roche logo

Roche··NCT01705730·71 enrolled

A Non-Interventional Study of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis

Completed· Roche logo

Roche··NCT01670045·43 enrolled

A Study of Tocilizumab in Combination With Disease-Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Moderate to Severe Active Rheumatoid Arthritis With an Inadequate Response to DMARDs

Completed· Roche logo

Roche·Phase 3·NCT00996606·58 enrolled

Interleukin-6 Inhibitors and Drug-drug Interactions in Patients With Rheumatoid Arthritis

Terminated·UUniversity of Southern Denmark·Phase 1/2·NCT04842981·3 enrolled

A Non-interventional Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis

Completed· Roche logo

Roche··NCT01562327·50 enrolled

To Evaluate 1 Year Extension Study of the Efficacy and Safety of Tocilizumab in Patients With Moderate to Severe Rheumatoid Arthritis

Completed·JJW Pharmaceutical·Phase 3·NCT01256736·89 enrolled

Use of Tocilizumab for Rheumatoid Arthritis (RA) in Daily Routine

Completed· Roche logo

Roche··NCT02809833·850 enrolled

Study to Compare the Efficacy of Tocilizumab With or Without Glucocorticoid Discontinuation in Rheumatoid Arthritis Participants

Completed· Roche logo

Roche·Phase 4·NCT02573012·314 enrolled

A Study of the Effect of Tocilizumab on Markers of Atherogenic Risk in Patients With Moderate to Severe Rheumatoid Arthritis

Completed· Roche logo

Roche·Phase 3·NCT00535782·132 enrolled

Tocilizumab27 trials

Success of Tocilizumab in RA Patients With Remission Induction and Sustained Efficacy After Discontinuation

Completed·SSURPRISE Study Group·Phase 4·NCT01120366·233 enrolled

Treatment of Chronic Active Antibody Mediated Rejection With Tocilizumab

Recruiting·SShahid Beheshti University of Medical Sciences·N/A·NCT07006532·50 enrolled

TOward the Lowest Effective DOse of Abatacept or Tocilizumab

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 4·NCT01557374·232 enrolled

Show 24 more trials

A Study to Evaluate Tocilizumab Treatment in a Real-Life Setting

Completed· Roche logo

Roche··NCT01664104·151 enrolled

A Study of Administration of RoActemra/Actemra (Tocilizumab) by Auto-injector Vs. Pre-filled Syringe in Healthy Volunteers

Completed· Roche logo

Roche·Phase 1·NCT01418989·239 enrolled

A Trial Using ANAKINRA, TOCILIZUMAB Alone or in Association With RUXOLITINIB in Severe Stage 2b and 3 of COVID19-associated Disease

Unknown status·AAssistance Publique Hopitaux De Marseille·Phase 3·NCT04424056·216 enrolled

Tocilizumab in Children With ACP

Active, not recruiting·UUniversity of Colorado, Denver·Phase 1·NCT03970226·9 enrolled

Tocilizumab Real-Life Human Factors (RLHFs) Validation Study

Completed· Roche logo

Roche·Phase 4·NCT02682823·91 enrolled

Pilot Study of Tocilizumab Monotherapy for Active Chronic Periaortitis

Completed·PPeking Union Medical College Hospital··NCT05133895·12 enrolled

Comparative Study of 3 Tocilizumab Products in Normal Healthy Volunteeers

Completed·SSyneos Health·Phase 1·NCT04885829·300 enrolled

Abatacept vs Tocilizumab for the Treatment of RA in TNF Alpha Inhibitor Inadequate Responders

Unknown status·LLille Catholic University·Phase 4·NCT03227419·224 enrolled

Efficacy of Tocilizumab for the Treatment of Acute AION Related to GCA

Unknown status·—·Phase 2·NCT04239196·58 enrolled

Tocilizumab and Tofacitinib in the Treatment of Vascular Behçet's Syndrome

Recruiting·PPeking Union Medical College Hospital·Phase 2·NCT05845723·81 enrolled

Use of Tocilizumab Drug Levels to Optimize Treatment in RA

Recruiting·—·Phase 4·NCT03895879·98 enrolled

Study to Describe Real World Drug Retention Rate of the Tocilizumab at One Year

Completed· Roche logo

Roche··NCT02608112·291 enrolled

PRONTO Trial (PRophylactic Versus ON-demand Use of TOcilizumab)

Recruiting·IInsel Gruppe AG, University Hospital Bern·Phase 2·NCT06430736·100 enrolled

A Longitudinal Study of ACTEMRA® (Tocilizumab) as Monotherapy in Highly Active NMOSD

Completed·FFu-Dong Shi·Phase 1/2·NCT03062579·10 enrolled

Mechanistic Studies of B- and T-Cell Function in RA Patients Treated With TNF Antagonists, Tocilizumab, or Abatacept

Terminated·—·Phase 4·NCT02353780·10 enrolled

Request for Single Patient IND for Compassionate/Emergency Use of Tocilizumab

No longer available·UUniversity of Oklahoma··NCT00862758

Immunoregulatory Mechanisms of Treg Cells Induced by Tocilizumab

Completed·FFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau··NCT02963402·35 enrolled

Tocilizumab in Patients With Schnitzler's Syndrome

Completed·KKaroline Krause·Phase 2·NCT03046381·8 enrolled

A Single-arm Trial of Prophylactic Tocilizumab for Acute GVHD Prevention After Haploidentical HSCT.

Unknown status·YYi Luo·Phase 2·NCT04688021·46 enrolled

To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN)

Completed· Sanofi logo

Sanofi·Phase 3·NCT01768572·202 enrolled

Tocilizumab in Chronic Inflammatory CPPD Disease

Not yet recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT07254637·80 enrolled

A Trial of Tocilizumab in ALS Subjects

Completed·BBarrow Neurological Institute·Phase 2·NCT02469896·22 enrolled

Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019

Unknown status·PPeking University First Hospital·N/A·NCT04310228·150 enrolled

A Study to Evaluate the Bioequivalence of Tocilizumab Following Subcutaneous Administration Via an Autoinjector (AI 1000-G2) Versus a Pre-Filled Syringe in Healthy Volunteers

Completed· Roche logo

Roche·Phase 1·NCT02678988·189 enrolled

COVID-1923 trials

Tocilizumab vs CRRT in Management of Cytokine Release Syndrome (CRS) in COVID-19

Unknown status·TTongji Hospital··NCT04306705·120 enrolled

Tocilizumab in COVID-19 Lahore General Hospital

Unknown status·LLahore General Hospital·Phase 1·NCT04560205·50 enrolled

Toclizumam Versus Dexamethasone in Severe Covid-19 Cases

Completed·SSouth Valley University·N/A·NCT04519385·69 enrolled

Show 20 more trials

Tocilizumab for SARS-CoV2 (COVID-19) Severe Pneumonitis

Unknown status·UUniversità Politecnica delle Marche·Phase 2·NCT04315480·38 enrolled

Tocilizumab Treatment in Patients With COVID-19

Active, not recruiting·IInstituto Nacional de Cancerologia de Mexico·Phase 2·NCT04363853·200 enrolled

Safety and Effectiveness Study of Tocilizumab in Patients With Severe COVID-19

Unknown status·HHospital Italiano de Buenos Aires··NCT04924829·300 enrolled

Trial of Tocilizumab for Treatment of Severe COVID-19: ARCHITECTS

Terminated·QQueen's Medical Center·Phase 3·NCT04412772·20 enrolled

Tocilizumab Versus Methylprednisolone in the Cytokine Release Syndrome of Patients With COVID-19

Terminated·HHospital Sao Domingos·Phase 2·NCT04377503·30 enrolled

Comparison of Tocilizumab Versus Tocilizumab/Infliximab in Patients With COVID-19-associated Cytokine Storm Syndrome

Completed·—··NCT04734678·153 enrolled

Comparative Therapeutic Efficacy and Safety of Different Antiviral and Anti Inflammatory Drugs in COVID-19 Patients.

Unknown status·OOctober 6 University·Phase 4·NCT04779047·150 enrolled

Efficacy of Tocilizumab in Modifying the Inflammatory Parameters of Patients With COVID-19 (COVITOZ-01)

Terminated·HHospital Universitario Ramon y Cajal·Phase 2·NCT04435717·26 enrolled

Treatment of COVID-19 Patients With Anti-interleukin Drugs

Completed·UUniversity Hospital, Ghent·Phase 3·NCT04330638·342 enrolled

Randomised Evaluation of COVID-19 Therapy

Recruiting·UUniversity of Oxford·Phase 3·NCT04381936·70,000 enrolled

Comparison of Tocilizumab Plus Dexamethasone vs. Dexamethasone for Patients With Covid-19

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT04476979·453 enrolled

Tocilizumab Versus Baricitinib in Patients With Severe COVID-19

Completed·UUniversity Hospital of Patras·N/A·NCT05082714·251 enrolled

Combination of Inhaled DNase, Baricitinib and Tocilizumab in Severe COVID-19

Unknown status·—·N/A·NCT05279391·150 enrolled

Low-dose Tocilizumab Versus Standard of Care in Hospitalized Patients With COVID-19

Terminated·UUniversity of Chicago·Phase 2·NCT04479358·85 enrolled

Study to Evaluate the Efficacy and Safety of Tocilizumab Versus Corticosteroids in Hospitalised COVID-19 Patients With High Risk of Progression

Unknown status·UUniversity of Malaya·Phase 3·NCT04345445·310 enrolled

LUSZ Treatment Efficacy in Hospitalized COVID-19 Patients

Unknown status·LLebanese University·Phase 1·NCT05925140·1,000 enrolled

A Study in Patients With COVID-19 and Respiratory Distress Not Requiring Mechanical Ventilation, to Compare Standard-of-care With Anakinra and Tocilizumab Treatment The Immunomodulation-CoV Assessment (ImmCoVA) Study

Unknown status·KKarolinska University Hospital·Phase 2·NCT04412291·120 enrolled

TOCILIZUMAB - An Option for Patients With COVID-19 Associated Cytokine Release Syndrome; A Single Center Experience

Completed·FFMH College of Medicine and Dentistry·Phase 4·NCT04730323·93 enrolled

Tocilizumab to Prevent Clinical Decompensation in Hospitalized, Non-critically Ill Patients With COVID-19 Pneumonitis

Completed·UUniversity of Chicago·Phase 2·NCT04331795·32 enrolled

Investigational Treatments for COVID-19 in Tertiary Care Hospital of Pakistan

Completed·UUNICEF·N/A·NCT04492501·600 enrolled

Giant Cell Arteritis6 trials

Efficacy of Tocilizumab in Association to Steroids in Giant Cell Arteritis With Cerebro-vascular Involvement

Active, not recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT04888221·66 enrolled

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Tocilizumab (TCZ) Administered to Participants With Giant Cell Arteritis (GCA).

Completed· Roche logo

Roche·Phase 1·NCT03923738·24 enrolled

Tocilizumab Dose-tapering and Interruption in Patients With Giant Cell Arteritis Achieving the Clinical Remission.

Unknown status·—·Phase 4·NCT03244709·15 enrolled

Show 3 more trials

Tocilizumab for Patients With Giant Cell Arteritis

Completed·IInsel Gruppe AG, University Hospital Bern·Phase 2·NCT01450137·30 enrolled

An Efficacy and Safety Study of Tocilizumab (RoActemra/Actemra) in Participants With Giant Cell Arteritis (GCA)

Completed· Roche logo

Roche·Phase 3·NCT01791153·251 enrolled

Giant Cell Arteritis Treatment With Ultra-short Glucocorticoids and Tocilizumab

Completed·IInsel Gruppe AG, University Hospital Bern·Phase 1/2·NCT03745586·18 enrolled

Multiple Myeloma4 trials

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

Recruiting·SSCRI Development Innovations, LLC·Phase 2·NCT05972135·100 enrolled

Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)

Completed· Roche logo

Roche·Phase 1·NCT03275103·355 enrolled

Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma

Active, not recruiting·EEmory University·Phase 1·NCT05391750·7 enrolled

Show 1 more trial

Safety and ASCT-related Symptom Burden Optimization of Tocilizumab in ASCT Following HD Melphalan Conditioning for Multiple Myeloma Patients

Unknown status·TThe First Affiliated Hospital of Soochow University·Phase 4·NCT05855122·48 enrolled

71 more indications

Takayasu arteritis4 trials

Multicentre, Randomized, Prospective Trial Evaluating the Efficacy and Safety of Infliximab to Tocilizumab in Refractory or Relapsing Takayasu Arteritis

Unknown status·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT04564001·50 enrolled

A Pilot Study in Severe Patients With Takayasu Arteritis.

Recruiting·SShanghai Zhongshan Hospital·Phase 4·NCT04300686·40 enrolled

Efficacy and Tolerance of Tocilizumab In Takayasu Arteritis

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT02101333·18 enrolled

Show 1 more trial

The Registry Study of Takayasu Arteritis in East China

Recruiting·SShanghai Zhongshan Hospital··NCT03893136·1,000 enrolled

Pneumonia4 trials

Tocilizumab and Cytokine Release Syndrome (CRS) In Covid-19 Pneumonia

Completed·SShaheed Zulfiqar Ali Bhutto Medical University··NCT04873141·24 enrolled

Effect of Tocilizumab on Intensive Care Patients With COVID-19 Pneumonia, a Retrospective Cohort Study

Completed·KKaradeniz Technical University··NCT04893031·213 enrolled

Serum IL-6 and Soluble IL-6 Receptor in Severe COVID-19 Pneumonia Treated With Tocilizumab

Unknown status·UUniversity Hospital for Infectious Diseases, Croatia··NCT04359667·30 enrolled

Show 1 more trial

The Effect of Tocilizumab on Procalcitonin and Other Biochemical and Clinical Markers in the Setting of COVID-19 Pneumonia

Completed·SSciberras, Stephen M.D.··NCT05035589·100 enrolled

Juvenile Idiopathic Arthritis3 trials

Single Patient Use of Tocilizumab in Systemic Onset Juvenile Idiopathic Arthritis

Terminated·TTufts Medical Center·N/A·NCT00868751·1 enrolled

A Study of Subcutaneously (SC) Administered Tocilizumab (TCZ) in Participants With Polyarticular-Course Juvenile Idiopathic Arthritis (pJIA)

Completed· Roche logo

Roche·Phase 1·NCT01904279·52 enrolled

Extension Study Evaluating the Safety and Efficacy of Subcutaneous Tocilizumab (RoActemra/Actemra) Administration in Systemic and Polyarticular-Course Juvenile Idiopathic Arthritis

Completed· Roche logo

Roche·Phase 1·NCT02165345·82 enrolled

Diffuse Large B-Cell Lymphoma3 trials

A Study to Evaluate Glofitamab as Single Agent Administered After Pretreatment With Obinutuzumab in Chinese Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Completed· Roche logo

Roche·Phase 1·NCT04657302·30 enrolled

Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Participants With Previously Untreated Diffuse Large B-Cell Lymphoma

Completed· Roche logo

Roche·Phase 1/2·NCT03677154·188 enrolled

A Study Evaluating the Safety and Efficacy of Glofitamab or Mosunetuzumab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade Large B-Cell Lymphoma

Completed· Roche logo

Roche·Phase 1·NCT04313608·23 enrolled

Polymyalgia Rheumatica3 trials

Lymphocyte and Cytokine Disturbances in Polymyalgia Rheumatica

Completed·UUniversity Hospital, Brest··NCT02888496·40 enrolled

A Study to Evaluate the Efficacy of Tocilizumab as a Remission-Induction and Glucocorticoid-Sparing Regimen in Subjects With New-Onset Polymyalgia Rheumatica (PMR- SPARE)

Completed·MMedical University of Vienna·Phase 3·NCT03263715·39 enrolled

Study of Tocilizumab to Treat Polymyalgia Rheumatica

Completed·HHospital for Special Surgery, New York·Phase 2·NCT01396317·10 enrolled

Interleukin3 trials

Interplay Between Interleukin-6 and Glucagon in the Regulation of Human Amino Acid and Protein Homeostasis

Completed·UUniversity Hospital, Basel, Switzerland·N/A·NCT06721910·26 enrolled

Role of Interleukin-6 in Exercise

Completed·UUniversity of Zurich·N/A·NCT01073826·56 enrolled

Theranostic Implication of Complementary Medicines Against Interleukin Receptors and Gp-130 Proteins

Completed·—·N/A·NCT04690920·200 enrolled

Lymphoma2 trials

A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma

Completed· Roche logo

Roche·Phase 1/2·NCT03677141·117 enrolled

Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma

Completed· Gilead logo

Gilead·Phase 1/2·NCT02348216·307 enrolled

Histiocytosis2 trials

Alemtuzumab or Tocilizumab in Combination With Etoposide and Dexamethasone for the Treatment of Adult Patients With Hemophagocytic Lymphohistiocytosis

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT02385110·18 enrolled

Tocilizumab and Hemophagocytic Lymphohistiocytosis (HLH)

Withdrawn·—·Phase 2·NCT02007239

Cytokine Release Syndrome2 trials

Tocilizumab for Cytokine Release Syndrome Prophylaxis in Haploidentical Transplantation

Completed·HHospital Universitario Dr. Jose E. Gonzalez·Phase 1/2·NCT03533101·30 enrolled

Study of the Tocilizumab Optimization Timing for CART19 Associated Cytokine Release Syndrome

Completed·UUniversity of Pennsylvania·Phase 1·NCT02906371·80 enrolled

Non-Small Cell Lung Cancer2 trials

A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)

Completed· Roche logo

Roche·Phase 1/2·NCT03337698·314 enrolled

Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy

Recruiting·—·Phase 1/2·NCT04691817·28 enrolled

Hepatocellular Carcinoma2 trials

Study of Tocilizumab in Patients With Hepatocellular Carcinoma (HCC) Undergoing Transarterial Chemoembolization (TACE)

Withdrawn·UUniversity of Michigan Rogel Cancer Center·Phase 1/2·NCT02997956

A Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases

Completed· Roche logo

Roche·Phase 1·NCT04338685·55 enrolled

Myocardial Infarction2 trials

ASSessing the Effect of Anti-IL-6 Treatment in Myocardial Infarction: The ASSAIL-MI Trial

Completed·OOslo University Hospital·Phase 2·NCT03004703·200 enrolled

Short-Term Application of Tocilizumab Following Myocardial Infarction

Completed·KKeesler Air Force Base Medical Center·N/A·NCT02419937·28 enrolled

Schizophrenia2 trials

An Open-Label Trial of Tocilizumab in Schizophrenia

Completed·BBrian Miller·Phase 1·NCT01696929·8 enrolled

Tocilizumab in Schizophrenia

Unknown status·BBrian Miller·Phase 1·NCT02874573·20 enrolled

Efficacy and Safety2 trials

Efficacy and Safety of Tocilizumab for TAO

Withdrawn·SSun Yat-sen University·Phase 2·NCT06087731

A Randomized, Controlled, Open-label, Multicenter Clinical Trial Comparing the Efficacy and Safety of a Precision Treatment Regimen Based on Clinical-molecular Phenotypes with a Conventional Treatment Regimen in the Treatment of Patients with Active Takayasu's Arteritis

Recruiting·SShanghai Zhongshan Hospital·Phase 4·NCT06498089·124 enrolled

Systemic Juvenile Idiopathic Arthritis2 trials

A Study of Subcutaneously Administered Tocilizumab in Participants With Systemic Juvenile Idiopathic Arthritis

Completed· Roche logo

Roche·Phase 1·NCT01904292·52 enrolled

A Study to Evaluate Pharmacokinetics and Safety of Tocilizumab (RoActemra/Actemra) in Participants Less Than 2 Years Old With Active Systemic Juvenile Idiopathic Arthritis (sJIA)

Completed· Roche logo

Roche·Phase 1·NCT01455701·11 enrolled

Polyarticular Juvenile Idiopathic Arthritis1 trial

A Study of Tocilizumab in Patients With Active Polyarticular Juvenile Idiopathic Arthritis

Completed· Roche logo

Roche·Phase 3·NCT00988221·188 enrolled

Ankylosing Spondylitis1 trial

A Study of RoActemra/Actemra (Tocilizumab) in Patients With Ankylosing Spondylitis Who Have Failed Treatment With NSAIDs

Terminated· Roche logo

Roche·Phase 3·NCT01209702·306 enrolled

Thyroid Eye Disease1 trial

Tocilizumab in Corticosteroid-Resistant Graves' Orbitopathy (Thyroid Eye Disease)

Recruiting·MMedical University of Warsaw··NCT06367517·30 enrolled

Systemic Sclerosis1 trial

A Study of the Efficacy and Safety of Tocilizumab in Participants With Systemic Sclerosis (SSc)

Completed· Roche logo

Roche·Phase 3·NCT02453256·212 enrolled

Acute Graft Versus Host Disease1 trial

Itacitinib and Tocilizumab for Steroid Refractory Acute Graft Versus Host Disease

Terminated·—·Phase 1·NCT04070781·1 enrolled

Pulmonary Arterial Hypertension1 trial

A Therapeutic Open Label Study of Tocilizumab in the Treatment of Pulmonary Arterial Hypertension

Completed·PPapworth Hospital NHS Foundation Trust·Phase 2·NCT02676947·29 enrolled

Transplantation1 trial

Tocilizumab for the Prevention of Graft Failure and GVHD in Haplo-Cord Transplantation

Active, not recruiting·WWeill Medical College of Cornell University·Phase 2·NCT04395222·21 enrolled

Metastatic Cancer1 trial

Tocilizumab Delivered Via Pleural and Peritoneal Catheters in Patients With Advanced Metastatic Cancer

Recruiting·—·Phase 1·NCT06016179·12 enrolled

Cardiac Arrest1 trial

IL-6 Inhibition for Modulating Inflammation After Cardiac Arrest

Completed·CChristian Hassager·Phase 2·NCT03863015·80 enrolled

Musculoskeletal Ultrasound1 trial

Musculoskeletal Ultrasound in Predicting Early Dose Titration With Tocilizumab

Completed·UUniversity of California, Los Angeles·Phase 4·NCT01717859·74 enrolled

Adamantinomatous Craniopharyngioma1 trial

ACTEMRA® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma

Recruiting·NNationwide Children's Hospital·Phase 2·NCT05233397·38 enrolled

Anticoagulation1 trial

Combined Anti-IL6R and Anticoagulation Therapy in Advanced NPC Patients

Active, not recruiting·—·N/A·NCT06442709·100 enrolled

Status Epilepticus1 trial

Possible Immuno-Modulatory Effect of Tocilizumab in Patients With Refractory Status Epilepticus.

Unknown status·—·Phase 3·NCT05346666·50 enrolled

Acute Myeloid Leukemia1 trial

Allogeneic or Haploidentical Stem Cell Transplant Followed By High-Dose Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Terminated·WWashington University School of Medicine·Phase 1·NCT02057770·25 enrolled

Methotrexate1 trial

Study of the Response and Cardiorespiratory Endurance in Early RA Patients Treated With Tocilizumab or Methotrexate

Completed·PPatrick Durez·N/A·NCT01245452·30 enrolled

Single Dose1 trial

Clinical Study of Single Dose IL-6R mAb Injection in RA Patients

Completed·BBeijing VDJBio Co., LTD.·Phase 1·NCT05232396·40 enrolled

Chronic Lymphocytic Leukemia1 trial

A Study Evaluating the Safety of Tocilizumab in Addition to Standard of Care Premedication Given Before Obinutuzumab + Chlorambucil in Participants With Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Comorbidities

Terminated· Roche logo

Roche·Phase 1·NCT02336048·38 enrolled

Dexamethasone1 trial

Immunomodulatory Effects of Dexamethasone, Tocilizumab and Anakinra During Experimental Human Endotoxemia

Recruiting·RRadboud University Medical Center·Phase 4·NCT06624436·52 enrolled

Familial Mediterranean Fever1 trial

Tocilizumab for the Treatment of Familial Mediterranean Fever

Completed·UUniversity Hospital Tuebingen·Phase 2·NCT03446209·30 enrolled

Esophageal Adenocarcinoma1 trial

Blood-borne Assessment of Stromal Activation in Esophageal Adenocarcinoma to Guide Tocilizumab Therapy

Active, not recruiting·—·Phase 2·NCT04554771·41 enrolled

HIV infection1 trial

AIDS 347: IL-6 Blockade in Treated HIV Infection

Completed·—·Phase 1/2·NCT02049437·34 enrolled

Leukemia1 trial

Pilot CAR-T Cells Therapy for Children/Young Adults With CD19+ R/R Leukemia/Lymphoma

Recruiting·—·Phase 1·NCT05333302·10 enrolled

Glucocorticoids1 trial

A Study to Evaluate the Use of Glucocorticoids in Combination With Tocilizumab in Daily Clinical Practice

Completed· Roche logo

Roche··NCT03291457·101 enrolled

Ovarian Cancer1 trial

Feasibility of the Combination of Chemotherapy (Carbo/Caelyx or Carbo/Doxorubicin) With Tocilizumab (mAb IL-6R) and Peg-Intron in Patients With Recurrent Ovarian Cancer

Completed·LLeiden University Medical Center·Phase 1/2·NCT01637532·21 enrolled

Colorectal Adenocarcinoma1 trial

A Phase Ib Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Cibisatamab in Combination With Atezolizumab After Pretreatment With Obinutuzumab in Participants With Previously Treated Metastatic Colorectal Adenocarcinoma

Terminated· Roche logo

Roche·Phase 1·NCT03866239·47 enrolled

Cardiovascular Disease1 trial

A Study of Tocilizumab in Comparison to Etanercept in Participants With Rheumatoid Arthritis and Cardiovascular Disease Risk Factors

Completed· Roche logo

Roche·Phase 4·NCT01331837·3,080 enrolled

Osteoarthritis1 trial

Effect of the Interleukin-6 Receptor Antagonist Tocilizumab in Patients With Hand Osteoarthritis

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT02477059·104 enrolled

Vasculitis1 trial

Biologics in Refractory Vasculitis: A Trial of Biologic Therapy for Refractory Primary Non-ANCA Associated Vasculitis

Terminated·—·Phase 2·NCT05168475·22 enrolled

Drug Repurposing1 trial

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - Tocilizumab vs Abatacept

Completed·—··NCT04529863·30,432 enrolled

Chronic Graft Versus Host Disease1 trial

Tocilizumab for Chronic Graft-versus-Host Disease Treatment

Withdrawn·FFred Hutchinson Cancer Center·Phase 2·NCT02174263

Hematological Malignancy1 trial

Nivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic Transplant

Terminated·MMedical College of Wisconsin·Phase 1·NCT03588936·2 enrolled

Kidney Transplant1 trial

A Safety Study of Tocilizumab to Improve Transplant Rates in Highly Sensitized Patients Awaiting Kidney Transplantation

Completed·—·Phase 1/2·NCT01594424·10 enrolled

Pancreatic Ductal Adenocarcinoma1 trial

A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

Completed· Roche logo

Roche·Phase 1/2·NCT03193190·341 enrolled

Relapsing Polychondritis1 trial

Tocilizumab for Relapsing Polychondritis

Withdrawn·MMcMaster Children's Hospital·Phase 2·NCT01104480

Hematopoietic Stem Cell Transplant1 trial

A Study of Tacrolimus/Methotrexate and Tocilizumab to Prevent Acute Graft-Versus-Host Disease (AGVD) After Allogeneic Hematopoietic Stem Cell Transplant

Completed·—·Phase 2·NCT02206035·45 enrolled

Necrosis1 trial

Comparing the Efficacy of Periarticular Bone Structure in Patients Treated With Either Tocilizumab or Tumor Necrosis Factor Blockers

Completed·UUniversity of Erlangen-Nürnberg Medical School··NCT02778789·66 enrolled

Melanoma1 trial

A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas

Completed· Roche logo

Roche·Phase 1·NCT04551352·20 enrolled

Breast Cancer1 trial

Trastuzumab and Pertuzumab in Combination With Tocilizumab in Subjects With Metastatic HER2 Positive Breast Cancer Resistant to Trastuzumab

Completed·UUniversity of Michigan Rogel Cancer Center·Phase 1·NCT03135171·11 enrolled

Respiratory Failure1 trial

Tocilizumab for Prevention of Respiratory Failure in Patients With Severe COVID-19 Infection

Terminated·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT04377659·9 enrolled

Recovery1 trial

IL-6 Regulation of Energy Stores During Recovery From an Acute Exercise Bout

Completed·HHelga Ellingsgaard·N/A·NCT05349149·30 enrolled

Locally Advanced1 trial

A Study of RO7617991 in Patients With Locally Advanced or Metastatic MAGE-A4-Positive Solid Tumors

Withdrawn· Roche logo

Roche·Phase 1·NCT06372574

Behcet's syndrome1 trial

Tocilizumab for the Treatment of Behcet's Syndrome

Terminated·NNYU Langone Health·Phase 2·NCT01693653·1 enrolled

Major Depressive Disorder1 trial

Tocilizumab Augmentation in Treatment-Refractory Major Depressive Disorder

Terminated·—·Phase 2·NCT02660528·3 enrolled

Inflammation1 trial

Tocilizumab for Renal Graft Inflammation

Completed·FFlavio Vincenti·Phase 2·NCT02108600·33 enrolled

Baricitinib1 trial

Efficacy of Ramdicivir and Baricitinib for the Treatment of Severe COVID 19 Patients

Unknown status·—·Phase 3·NCT04693026·150 enrolled

Locally Advanced or Metastatic Solid Tumors1 trial

A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors

Terminated· Takeda logo

Takeda·Phase 1/2·NCT05070247·61 enrolled

Metastatic Solid Tumors1 trial

In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors

Active, not recruiting·UUniversity of Southern California·Phase 1·NCT04616248·14 enrolled

Major Depression1 trial

Triple-Blind Randomized Clinical Trial of Tocilizumab vs Placebo: Potential Use of an IL-6 Antagonist as an Adjuvant to Standard Treatment for Treatment-Resistant Major Depression in the Brazilian Public Health System (SUS)

Not yet recruiting·HHospital de Clinicas de Porto Alegre·Phase 2·NCT07052058·32 enrolled

Uveitis1 trial

Study of the Safety, Tolerability, and Bioactivity of Tocilizumab On Patients With Non-infectious UVEITIS: The STOP-UVEITIS Study

Unknown status·UUniversity of Nebraska·Phase 1/2·NCT01717170·36 enrolled

Acute Myocardial Infarction1 trial

Low-Dose Dobutamine and Single-Dose Tocilizumab in Acute Myocardial Infarction With High Risk of Cardiogenic Shock

Active, not recruiting·RRigshospitalet, Denmark·Phase 2·NCT05350592·100 enrolled

Nephrectomy1 trial

Evaluation of the Safety of Use of Anti-IL6 Receptor Antibodies to Reduce Allo-sensitization Post Allograft Nephrectomy

Completed·UUniversity Hospital, Toulouse·Phase 2·NCT04779957·18 enrolled

Pancreatic Cancer1 trial

Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab in Pancreatic Cancer Patients

Completed·HHerlev Hospital·Phase 2·NCT02767557·147 enrolled

Ischemic stroke1 trial

Effect of Interleukin-6 Receptor Inhibition in Patients With Ischemic Stroke Undergoing Endovascular Treatment

Completed·SSuzhou Municipal Hospital of Anhui Province·Phase 2/3·NCT06238024·108 enrolled

Obesity1 trial

Meal-regulated Substrate Metabolism, Influence of Obesity and IL-6

Completed·RRigshospitalet, Denmark·N/A·NCT04687540·25 enrolled

Treatment1 trial

CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALL

Unknown status·FFederal Research Institute of Pediatric Hematology, Oncology and Immunology·Phase 1/2·NCT03467256·18 enrolled

Unspecified1 trial

Plan Development for Giving Teclistamab in the Outpatient Setting

Recruiting·UUniversity Health Network, Toronto·Phase 4·NCT06251076·15 enrolled

Regulatory

FDA Approval Timeline[5]

Jan 8, 2010

ACTEMRA

NDA BLA125276

Jan 8, 2010

ACTEMRA

BLA BLA125276

Jan 4, 2011

ACTEMRA

NDA BLA125276

Jan 4, 2011

ACTEMRA

NDA BLA125276

Jan 4, 2011

ACTEMRA

NDA BLA125276

Apr 15, 2011

ACTEMRA

NDA BLA125276

Apr 15, 2011

ACTEMRA

NDA BLA125276

Jun 20, 2012

ACTEMRA

NDA BLA125276

Aug 13, 2012

ACTEMRA

NDA BLA125276

Oct 11, 2012

ACTEMRA

NDA BLA125276

Apr 29, 2013

ACTEMRA

NDA BLA125276

Jul 2, 2013

ACTEMRA

NDA BLA125276

Oct 21, 2013

ACTEMRA

NDA BLA125472

Oct 21, 2013

ACTEMRA

NDA BLA125276

Oct 21, 2013

ACTEMRA

BLA BLA125472

Nov 13, 2014

ACTEMRA

NDA BLA125276

Aug 18, 2015

ACTEMRA

NDA BLA125276

Aug 18, 2015

ACTEMRA

NDA BLA125472

Sep 23, 2016

ACTEMRA

NDA BLA125472

Sep 23, 2016

ACTEMRA

NDA BLA125276

Mar 30, 2017

ACTEMRA

NDA BLA125472

Mar 30, 2017

ACTEMRA

NDA BLA125276

May 22, 2017

ACTEMRA

NDA BLA125472

May 22, 2017

ACTEMRA

NDA BLA125276

Aug 30, 2017

ACTEMRA

NDA BLA125276

Mar 22, 2018

ACTEMRA

NDA BLA125472

Mar 22, 2018

ACTEMRA

NDA BLA125276

May 11, 2018

ACTEMRA

NDA BLA125472

May 11, 2018

ACTEMRA

NDA BLA125276

May 17, 2018

ACTEMRA

NDA BLA125472

May 17, 2018

ACTEMRA

NDA BLA125276

Sep 12, 2018

ACTEMRA

NDA BLA125276

Sep 12, 2018

ACTEMRA

NDA BLA125472

Nov 19, 2018

ACTEMRA

NDA BLA125472

Nov 19, 2018

ACTEMRA

NDA BLA125276

Dec 20, 2018

ACTEMRA

NDA BLA125472

Dec 20, 2018

ACTEMRA

NDA BLA125276

Apr 11, 2019

ACTEMRA

NDA BLA125276

Apr 11, 2019

ACTEMRA

NDA BLA125276

Apr 11, 2019

ACTEMRA

NDA BLA125472

Jun 11, 2019

ACTEMRA

NDA BLA125472

Jun 11, 2019

ACTEMRA

NDA BLA125276

May 28, 2020

ACTEMRA

NDA BLA125276

May 28, 2020

ACTEMRA

NDA BLA125472

Mar 4, 2021

ACTEMRA

NDA BLA125276

Mar 4, 2021

ACTEMRA

NDA BLA125472

Oct 22, 2021

ACTEMRA

NDA BLA125472

Oct 22, 2021

ACTEMRA

NDA BLA125276

Feb 28, 2022

ACTEMRA

NDA BLA125472

Feb 28, 2022

ACTEMRA

NDA BLA125276

Dec 21, 2022

ACTEMRA

NDA BLA125472

Dec 21, 2022

ACTEMRA

NDA BLA125276

Sep 29, 2023

TOFIDENCE

BLA BLA761354

Sep 19, 2024

ACTEMRA

NDA BLA125276

Sep 19, 2024

ACTEMRA

NDA BLA125472

Sep 20, 2024

ACTEMRA

NDA BLA125472

Sep 20, 2024

ACTEMRA

NDA BLA125276

Dec 10, 2024

ACTEMRA

NDA BLA125472

Dec 10, 2024

ACTEMRA

NDA BLA125276

Jan 24, 2025

AVTOZMA

BLA BLA761420

Aug 8, 2025

ACTEMRA

NDA BLA125276

Aug 8, 2025

ACTEMRA

NDA BLA125472

Dec 10, 2025

ACTEMRA

NDA BLA125472

Dec 10, 2025

ACTEMRA

NDA BLA125276

Jan 21, 2026

AVTOZMA

BLA BLA761498

Sources

References

[1]
ClinicalTrials.gov — 453 trial records for Tocilizumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Actemra drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Tocilizumab compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Tocilizumab. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (BLA BLA761498). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Interleukin-6 Receptor Alpha Subunit Inhibitor[3]
Modality: Monoclonal antibody[3]
Highest Phase: Approved[1]
Company: Roche